{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:04:40Z","timestamp":1778508280909,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2006,7,1]]},"DOI":"10.1038\/nbt1228","type":"journal-article","created":{"date-parts":[[2006,7,13]],"date-time":"2006-07-13T15:08:00Z","timestamp":1152803280000},"page":"805-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":723,"title":["Global mapping of pharmacological space"],"prefix":"10.1038","volume":"24","author":[{"given":"Gaia V","family":"Paolini","sequence":"first","affiliation":[]},{"given":"Richard H B","family":"Shapland","sequence":"additional","affiliation":[]},{"given":"Willem P","family":"van Hoorn","sequence":"additional","affiliation":[]},{"given":"Jonathan S","family":"Mason","sequence":"additional","affiliation":[]},{"given":"Andrew L","family":"Hopkins","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2006,7,13]]},"reference":[{"key":"BFnbt1228_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1741-8364(04)02408-4","volume":"2","author":"A Schuffenhauer","year":"2004","unstructured":"Schuffenhauer, A. & Jacoby, E. Annotating and mining the ligand-target chemogenomics knowledge space. Drug Discov. Today: BIOSILICO 2, 190\u2013200 (2004).","journal-title":"Drug Discov. Today: BIOSILICO"},{"key":"BFnbt1228_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1126\/science.1083395","volume":"300","author":"RL Strausberg","year":"2003","unstructured":"Strausberg, R.L. & Schreiber, S.L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294\u2013295 (2003).","journal-title":"Science"},{"key":"BFnbt1228_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","volume":"275","author":"JN Weinstein","year":"1997","unstructured":"Weinstein, J.N. et al. An information intensive approach to the molecular pharmacology of cancer. Science 275, 343\u2013349 (1997).","journal-title":"Science"},{"key":"BFnbt1228_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/107385840000600408","volume":"6","author":"BL Roth","year":"2000","unstructured":"Roth, B.L., Kroeze, W.K., Patel, S. & Lopez, E. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrasment of riches? Neuroscientist 6, 252\u2013262 (2000).","journal-title":"Neuroscientist"},{"key":"BFnbt1228_CR5","first-page":"470","volume":"6","author":"CM Krejsa","year":"2003","unstructured":"Krejsa, C.M. et al. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. Develop. 6, 470\u2013480 (2003).","journal-title":"Curr. Opin. Drug Discov. Develop."},{"key":"BFnbt1228_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/ci025634z","volume":"43","author":"D Horvath","year":"2003","unstructured":"Horvath, D. & Jeandenans, C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J. Chem. Inf. Comput. Sci. 43, 680\u2013690 (2003).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"BFnbt1228_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.chembiol.2003.08.009","volume":"10","author":"DE Root","year":"2003","unstructured":"Root, D.E., Flaherty, S.P., Kelley, B.P. & Stockwell, B. Biological mechanism profiling using an annotated compound library. Chem. Biol. 10, 881\u2013892 (2003).","journal-title":"Chem. Biol."},{"key":"BFnbt1228_CR8","first-page":"173","volume":"5","author":"A Wallqvist","year":"2003","unstructured":"Wallqvist, A. et al. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Prog. Cell Cycle Res. 5, 173\u2013179 (2003).","journal-title":"Prog. Cell Cycle Res."},{"key":"BFnbt1228_CR9","volume-title":"Knowledge Discovery in Databases","author":"G Piatetski-Shapiro","year":"1992","unstructured":"Piatetski-Shapiro, G. & Frawley, W. Knowledge Discovery in Databases (MIT Press, Cambridge, 1992)."},{"key":"BFnbt1228_CR10","volume-title":"Handbook of Data Mining and Knowledge Discovery","author":"W Kl\u00f6sgen","year":"2002","unstructured":"Kl\u00f6sgen, W. & Zytkow, J.M. (eds.). Handbook of Data Mining and Knowledge Discovery (Oxford University Press, Oxford, 2002)."},{"key":"BFnbt1228_CR11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/nbt1196-1516","volume":"14","author":"J Drews","year":"1996","unstructured":"Drews, J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14, 1516\u20131518 (1996).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt1228_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nbt1297-1318","volume":"15","author":"J Drews","year":"1997","unstructured":"Drews, J. & Ryser, S. Classic drug targets. Nat. Biotechnol. 15, 1318\u20131319 (1997).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt1228_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnbt1228_CR14","first-page":"310","volume":"6","author":"JB Golden","year":"2003","unstructured":"Golden, J.B. Prioritizing the human genome: knowledge management for drug discovery. Curr. Opin. Drug Discov. Develop. 6, 310\u2013316 (2003).","journal-title":"Curr. Opin. Drug Discov. Develop."},{"key":"BFnbt1228_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Del. Rev."},{"key":"BFnbt1228_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ddr.430080103","volume":"8","author":"S Van Gestel","year":"1986","unstructured":"Van Gestel, S. & Schuermans, V. Thirty-three years of drug discovery and research with Dr. Paul Janssen. Drug Dev. Res. 8, 1\u201313 (1986).","journal-title":"Drug Dev. Res."},{"key":"BFnbt1228_CR17","volume-title":"Drug Prototypes and Their Exploitation","author":"W Sneader","year":"1996","unstructured":"Sneader, W. Drug Prototypes and Their Exploitation (Wiley, London, 1996)."},{"key":"BFnbt1228_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1021\/jm030480f","volume":"47","author":"CG Wermuth","year":"2004","unstructured":"Wermuth, C.G. Selective optimization of side activities: another way for drug discovery. J. Med. Chem. 47, 1303\u20131314 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR19","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1021\/jm030266r","volume":"46","author":"SL McGovern","year":"2003","unstructured":"McGovern, S.L., Helfand, B.T., Feng, B. & Shoichet, B.K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46, 4265\u20134272 (2003).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbapap.2003.11.028","volume":"1697","author":"M Vieth","year":"2004","unstructured":"Vieth, M. et al. Kinomics\u2014structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697, 243\u2013257 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnbt1228_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1359-6446(05)03477-X","volume":"10","author":"M Vieth","year":"2005","unstructured":"Vieth, M., Sutherland, J.J., Robertson, D.H. & Campbell, R.M. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 10, 839\u2013846 (2005).","journal-title":"Drug Discov. Today"},{"key":"BFnbt1228_CR22","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1016\/S1074-5521(99)80013-1","volume":"6","author":"SV Frye","year":"1999","unstructured":"Frye, S.V. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem. Biol. 6, R3\u2013R7 (1999).","journal-title":"Chem. Biol."},{"key":"BFnbt1228_CR23","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1021\/jm0303195","volume":"47","author":"X Xia","year":"2004","unstructured":"Xia, X., Maliski, E.G., Gallant, P. & Rogers, D. Classification of kinase inhibitors using a Bayesian model. J. Med. Chem. 47, 4463\u20134470 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/1087057105281365","volume":"10","author":"D Rogers","year":"2005","unstructured":"Rogers, D., Brown, R.D. & Hahn, M. Using extended-connectivity fingerprints with laplacian-modified Bayesian analysis in high-throughput screening follow-up. J. Biomol. Screen. 10, 682\u2013686 (2005).","journal-title":"J. Biomol. Screen."},{"key":"BFnbt1228_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nature03193","volume":"432","author":"C Lipinski","year":"2004","unstructured":"Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855\u2013861 (2004).","journal-title":"Nature"},{"key":"BFnbt1228_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/jm030267j","volume":"47","author":"M Vieth","year":"2004","unstructured":"Vieth, M. et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224\u2013232 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR27","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1021\/jm021053p","volume":"46","author":"MC Wenlock","year":"2003","unstructured":"Wenlock, M.C., Austin, R.P., Barton, P., Davis, A.M. & Leeson, P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46, 1250\u20131256 (2003).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR28","doi-asserted-by":"crossref","unstructured":"Blake, J.F. Examination of the computed molecular properties of compounds selected for clinical development. Biotechniques (June) Suppl.,16\u201320 (2003).","DOI":"10.2144\/blakejun03"},{"key":"BFnbt1228_CR29","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/jm970666c","volume":"41","author":"A Ajay","year":"1998","unstructured":"Ajay, A., Walters, W.P. & Murcko, M.A. Can we learn to distinguish between \u201cdrug-like\u201d and \u201cnondrug-like\u201d molecules? J. Med. Chem. 41, 3314\u20133324 (1998).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235\u2013249 (2000).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"BFnbt1228_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1021\/cc990032m","volume":"1","author":"J Wang","year":"1999","unstructured":"Wang, J. & Ramnarayan, K. Towards designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. J. Comb. Chem. 1, 524\u2013533 (1999).","journal-title":"J. Comb. Chem."},{"key":"BFnbt1228_CR32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1367-5931(99)80058-1","volume":"3","author":"WP Walters","year":"1999","unstructured":"Walters, W.P. Ajay & Murcko, M.A. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 3, 384\u2013387 (1999).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"BFnbt1228_CR33","first-page":"102","volume":"4","author":"BL Podlogar","year":"2001","unstructured":"Podlogar, B.L., Muegge, I. & Brice, L.J. Computational methods to estimate drug development paramenters. Curr. Opin. Drug Discov. Devel. 4, 102\u2013109 (2001).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"BFnbt1228_CR34","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1021\/jm015507e","volume":"44","author":"I Muegge","year":"2001","unstructured":"Muegge, I., Heald, S.L. & Brittelli, D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 44, 1841\u20131846 (2001).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR35","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber, D.F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615\u20132623 (2002).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR36","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0960-894X(02)00244-5","volume":"12","author":"JR Proudfoot","year":"2002","unstructured":"Proudfoot, J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 12, 1647\u20131650 (2002).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnbt1228_CR37","first-page":"540","volume":"5","author":"WJ Egan","year":"2002","unstructured":"Egan, W.J., Walters, W.P. & Murcko, M.A. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discov. Devel. 5, 540\u2013549 (2002).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"BFnbt1228_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0169-409X(02)00003-0","volume":"54","author":"WP Walters","year":"2002","unstructured":"Walters, W.P. & Murcko, M.A. Prediction of 'drug-likeness'. Adv. Drug Deliv. Rev. 54, 255\u2013271 (2002).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnbt1228_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 23, 302\u2013321 (2003).","journal-title":"Med. Res. Rev."},{"key":"BFnbt1228_CR40","first-page":"470","volume":"7","author":"MS Lajiness","year":"2004","unstructured":"Lajiness, M.S., Vieth, M. & Erickson, J. Molecular properties that influence oral drug-like behavior. Curr. Opin. Drug Discov. Devel. 7, 470\u2013477 (2004).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"BFnbt1228_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/35038557","volume":"1","author":"BR Stockwell","year":"2000","unstructured":"Stockwell, B.R. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1, 116\u2013125 (2000).","journal-title":"Nat. Rev. Genet."},{"key":"BFnbt1228_CR42","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1126\/science.1105511","volume":"306","author":"CP Austin","year":"2004","unstructured":"Austin, C.P., Brady, L.S., Insel, T.R. & Collins, F.S. NIH Molecular Libraries Initiative. Science 306, 1138\u20131139 (2004).","journal-title":"Science"},{"key":"BFnbt1228_CR43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1021\/ci010385k","volume":"42","author":"A Schuffenhauer","year":"2002","unstructured":"Schuffenhauer, A. et al. An ontology for pharmaceutical ligands and its applications for in silico screening and library design. J. Chem. Inf. Comput. Sci. 42, 947\u2013955 (2002).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"BFnbt1228_CR44","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1016\/j.febslet.2005.07.039","volume":"579","author":"HJ Feldman","year":"2005","unstructured":"Feldman, H.J., Dumontier, M., Ling, S., Haider, N. & Hogue, C.W. CO: A chemical ontology for identification of functional groups and semantic comparison of small molecules. FEBS Lett. 579, 4685\u20134691 (2005).","journal-title":"FEBS Lett."},{"key":"BFnbt1228_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth, B.L., Sheffler, D.J. & Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353\u2013359 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnbt1228_CR46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/437942a","volume":"437","author":"S Frantz","year":"2005","unstructured":"Frantz, S. Drug discovery: playing dirty. Nature 437, 942\u2013943 (2005).","journal-title":"Nature"},{"key":"BFnbt1228_CR47","volume-title":"Database Systems, A Practical Approach to Design, Implementation and Management","author":"T Connolly","year":"2002","unstructured":"Connolly, T. & Begg, C. Database Systems, A Practical Approach to Design, Implementation and Management., edn. 3 (Addison Wesley, Reading, MA, 2002)."},{"key":"BFnbt1228_CR48","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"BFnbt1228_CR49","unstructured":"R Core Development Team. A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, 2005)."},{"key":"BFnbt1228_CR50","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/jm00378a021","volume":"27","author":"PR Andrews","year":"1984","unstructured":"Andrews, P.R., Craik, D.J. & Martin, J.L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 27, 1648\u20131657 (1984).","journal-title":"J. Med. Chem."},{"key":"BFnbt1228_CR51","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","volume":"9","author":"AL Hopkins","year":"2004","unstructured":"Hopkins, A.L., Groom, C.R. & Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9, 430\u2013431 (2004).","journal-title":"Drug Discov. Today"},{"key":"BFnbt1228_CR52","doi-asserted-by":"publisher","first-page":"9997","DOI":"10.1073\/pnas.96.18.9997","volume":"96","author":"ID Kuntz","year":"1999","unstructured":"Kuntz, I.D., Chen, K., Sharp, K.A. & Kollman, P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA 96, 9997\u201310002 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nbt1228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt1228","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt1228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:36:03Z","timestamp":1744342563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nbt1228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7,1]]}},"alternative-id":["BFnbt1228"],"URL":"https:\/\/doi.org\/10.1038\/nbt1228","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1040792.489836","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1040792.497640","asserted-by":"object"}]},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]},"assertion":[{"value":"13 July 2006","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All of the authors were or are employees (or contract employees) of Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}